Tarsus is paying $450 million upfront for Alkeus – made up of $270 million in cash and $180 million in stock – with another ...

Takeda's orexin agonist Orzeyful has been approved in the US to treat narcolepsy type 1 (NT1) in adults, becoming the first ...

For an emerging biopharma company developing an innovative therapy for a rare condition, 2026 presents a dilemma that may ...

The CDC has permanent leadership in place for the first time since August 2025, after the US Senate confirmed the appointment ...

A Netherlands-based compounding pharmacy has been ordered to stop distributing a compounded nasal spray formulation of Novo Nordisk's GLP-1 agonist semaglutide in a test of the country's pharmacy ...

Roche's Japanese unit Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia. Chugai is paying JP 15 billion ($98 million) ...

There is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, according to ...

There's a change at the helm of Johnson & Johnson's pharma division in the offing, as executive vice president Jennifer ...

For decades, direct-to-consumer (DTC) advertising has been a defining feature of the US healthcare system. Across the nation, ...

Patients in England with ultra-rare kidney disease nephropathic cystinosis will soon be able to access a therapy that has ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...

Sentiment towards Novo Nordisk was also hit by the acknowledgement that it has decided to abandon the development of ...